click below
click below
Normal Size Small Size show me how
Parkinson Disease
ch 17 nervous system
| Question | Answer |
|---|---|
| Parkinson disease | progressive condition associated with the loss or deficiency of dopamine; drug therapy focuses on increasing dopamine and decreasing acetylcholine |
| TRAP symptoms | tremor, rigidity, akinesia (loss of normal motor function), and postural instability |
| main therapies for PD | levodopa plus carbidopa, dopamine agonists, and MAO-B inhibitors |
| five classes of PD drugs | levodopa and carbidopa, dopamine agonists, MAO-B inhibitors, anticholinergics, and catechol-o-methyl tranferase (COMT) inhibtors |
| Sinemet | carbidopa and levodopa *carbidopa and levodopa |
| Stalevo | carbidopa, levodopa, and entacapone *carbidopa and levodopa |
| Requip | ropinirole *dopamine agonists |
| Mirapex | pramipexole *dopamine agonists |
| Azilect | rasagiline *MAO-B inhibitors |
| Eldrepyl, Zelapar | selegiline *MAO-B inhibitors |
| Cogentin | benztropine *anticholinergics |
| Artane | trihexyphenidyl *anticholinergics |
| Symmetrel | amantadine *anticholinergics |
| Comtan | entacapone *COMT inhibitors |
| Tasmar | tolcapone *COMT inhibitors |